Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.38 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.38 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FABP1 | P07148 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380286 | 1.00 | KDM4E (0.47) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| SCHEMBL30595394 | 1.00 | KDM4E (0.47) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| SCHEMBL4872637 | 1.00 | KDM4E (0.47) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| Water SCHEMBL27557581 | 0.98 | KDM4E (0.46) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| SCHEMBL38652300 | 0.98 | KDM4E (0.46) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| Potassium Ion SCHEMBL9114094 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| SCHEMBL3169148 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| SCHEMBL7065753 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| Lithium Ion SCHEMBL10680313 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 | |
| SCHEMBL20166759 | 0.96 | KDM4E (0.42) | KDM4EALDH1A1HPGDL3MBTL1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210077639-A1 | RADIOPHARMACEUTICAL PRODUCTS | GE HEALTHCARE LTD (GB) | 2021-03-18 | — | — | US | claimed |
| US-10328164-B2 | Radiopharmaceutical products | GE HEALTHCARE LIMITED (GB) | 2019-06-25 | — | — | US | claimed |
| US-20260102523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | JUBILANT DRAXIMAGE INC (CA) | 2026-04-16 | — | — | US | disclosed |
| US-12440583-B2 | Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof | JUBILANT DRAXIMAGE, INC. (CA) | 2025-10-14 | — | — | US | disclosed |
| US-20250312364-A1 | METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2025-10-09 | — | — | US | disclosed |
| CN-118831183-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240307420-A1 | IMPROVED METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2024-09-19 | — | — | US | disclosed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3592735-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TETROFOSMIN OR ACID ADDITION SALT THEREOF | JUBILANT GENERICS LTD FORMERLY A DIVISION OF JUBILANT LIFE SCIENCES LTD (IN) | 2024-03-20 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20100236958-A1 | RADIOPHARMACEUTICAL COMPOSITION | GE HEALTHCARE LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-20090297442-A1 | RADIOPHARMACEUTICAL PRODUCTS | GE HEALTHCARE LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1345630-B1 | STABILISED RADIOPHARMACEUTICAL COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| EP-1824525-B1 | STABILISED 99mTC COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1824525-A1 | STABILISED 99mTC COMPOSITIONS | GE Healthcare Limited (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064175-A1 | STABILISED 99mTC COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| US-7052672-B2 | Stabilized radiopharmaceutical compositions | GE HEALTHCARE LIMITED (GB) | 2006-05-30 | — | — | US | disclosed |
| EP-1345630-A1 | STABILISED RADIOPHARMACEUTICAL COMPOSITIONS | GE Healthcare Limited (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053192-A1 | STABILISED RADIOPHARMACEUTICAL COMPOSITIONS | AMERSHAM PLC (GB) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297442-A1 | RADIOPHARMACEUTICAL PRODUCTS | MVD, TRHDE, EEF1E1 | CA2 4450/4885CA4 3599/4885PTGS1 3292/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA2 150/4885CA4 623/4885PTGS1 210/4885 |
| US-20210077639-A1 | RADIOPHARMACEUTICAL PRODUCTS | MVD, TRHDE, EEF1E1 | CA2 4450/4885CA4 3599/4885PTGS1 3292/4885 |
| US-20100236958-A1 | RADIOPHARMACEUTICAL COMPOSITION | MEN1, TYMP, KIT | CA2 2233/4885CA4 1927/4885PTGS1 4284/4885 |
| US-10328164-B2 | Radiopharmaceutical products | MVD, TRHDE, EEF1E1 | CA2 4450/4885CA4 3599/4885PTGS1 3292/4885 |
| US-20260102523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TREH, CD68, THPO | CA2 10/4885CA4 60/4885PTGS1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.